Dopamine agonists as primary treatment in Parkinson's disease.
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use; D004185:Disability Evaluation; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008090:Lisuride / Q000031:analogs & derivatives / Q000627:therapeutic use; D008134:Long-Term Care; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000627:therapeutic use; D011954:Receptors, Dopamine / Q000187:drug effects*
D000978:Antiparkinson Agents; D004873:Ergolines; D011954:Receptors, Dopamine; C006208:dironyl; D010479:Pergolide; C016871:CM 29-712; C031648:etisulergine; D001971:Bromocriptine; D007980:Levodopa; D008090:Lisuride; C031649:mesulergine